Senti Biosciences (SNTI) Accumulated Depreciation & Amortization (2021 - 2025)

Senti Biosciences has reported Accumulated Depreciation & Amortization for 5 years, with the latest figure at $13.1 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 36.71% year-over-year to $13.1 million; the trailing twelve-month figure through Dec 2025 stood at $13.1 million (up 36.71% YoY), and the FY2025 full-year result was $13.1 million, up 36.71% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $13.1 million, up from $12.2 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $13.1 million in Q4 2025, with the low at $1.7 million in Q4 2021.
• Average Accumulated Depreciation & Amortization over 5 years is $6.8 million, with a median of $6.6 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization jumped 109.2% in 2023 and jumped 36.71% in 2025.
• Tracing SNTI's Accumulated Depreciation & Amortization over 5 years: stood at $1.7 million in 2021, then surged by 78.55% to $3.0 million in 2022, then jumped by 109.2% to $6.2 million in 2023, then jumped by 54.5% to $9.6 million in 2024, then soared by 36.71% to $13.1 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $13.1 million (Q4 2025), $12.2 million (Q3 2025), and $11.3 million (Q2 2025), per Business Quant data.

Peer Comparison